Literature DB >> 27112376

ChAcNLS, a Novel Modification to Antibody-Conjugates Permitting Target Cell-Specific Endosomal Escape, Localization to the Nucleus, and Enhanced Total Intracellular Accumulation.

Simon Beaudoin1, Andreanne Rondeau1, Olivier Martel1, Marc-Andre Bonin1, Johan E van Lier1, Jeffrey V Leyton1.   

Abstract

The design of antibody-conjugates (ACs) for delivering molecules for targeted applications in humans has sufficiently progressed to demonstrate clinical efficacy in certain malignancies and reduced systemic toxicity that occurs with standard nontargeted therapies. One area that can advance clinical success for ACs will be to increase their intracellular accumulation. However, entrapment and degradation in the endosomal-lysosomal pathway, on which ACs are reliant for the depositing of their molecular payload inside target cells, leads to reduced intracellular accumulation. Innovative approaches that can manipulate this pathway may provide a strategy for increasing accumulation. We hypothesized that escape from entrapment inside the endosomal-lysosomal pathway and redirected trafficking to the nucleus could be an effective approach to increase intracellular AC accumulation in target cells. Cholic acid (ChAc) was coupled to the peptide CGYGPKKKRKVGG containing the nuclear localization sequence (NLS) from SV-40 large T-antigen, which is termed ChAcNLS. ChAcNLS was conjugated to the mAb 7G3 (7G3-ChAcNLS), which has nanomolar affinity for the cell-surface leukemic antigen interleukin-3 receptor-α (IL-3Rα). Our aim was to determine whether 7G3-ChAcNLS increased intracellular accumulation while retaining nanomolar affinity and IL-3Rα-positive cell selectivity. Competition ELISA and cell treatment assays were performed. Cell fractionation, confocal microscopy, flow cytometry, and Western blot techniques were used to determine the level of antibody accumulation inside cells and in corresponding nuclei. In addition, the radioisotope copper-64 ((64)Cu) was also utilized as a surrogate molecular cargo to evaluate nuclear and intracellular accumulation by radioactivity counting. 7G3-ChAcNLS effectively escaped endosome entrapment and degradation resulting in a unique intracellular distribution pattern. mAb modification with ChAcNLS maintained 7G3 nM affinity and produced high selectivity for IL-3Rα-positive cells. In contrast, 7G3 ACs with the ability to either escape endosome entrapment or traffic to the nucleus was not superior to 7G3-ChAcNLS for increasing intracellular accumulation. Transportation of (64)Cu when complexed to 7G3-ChAcNLS also resulted in increased nuclear and intracellular radioactivity accumulation. Thus, ChAcNLS is a novel mAb functionalizing technology that demonstrates its ability to increase AC intracellular accumulation in target cells through escaping endosome entrapment coupled to nuclear trafficking.

Entities:  

Keywords:  antibody-conjugates; endosome escape; intracellular accumulation; nuclear localization

Mesh:

Substances:

Year:  2016        PMID: 27112376     DOI: 10.1021/acs.molpharmaceut.6b00075

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  7 in total

1.  Targeting IL-5Rα with antibody-conjugates reveals a strategy for imaging and therapy for invasive bladder cancer.

Authors:  Michel Paquette; Luis-Guillermo Vilera-Perez; Simon Beaudoin; Nadia Ekindi-Ndongo; Pierre-Luc Boudreaut; Marc-Andre Bonin; Marie-Claude Battista; M'hamed Bentourkia; Angel F Lopez; Roger Lecomte; Eric Marsault; Brigitte Guérin; Robert Sabbagh; Jeffrey V Leyton
Journal:  Oncoimmunology       Date:  2017-05-19       Impact factor: 8.110

2.  Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting.

Authors:  Simon Beaudoin; Michel Paquette; Laurent Fafard-Couture; Mylene A Tremblay; Roger Lecomte; Brigitte Guérin; Jeffrey V Leyton
Journal:  J Vis Exp       Date:  2018-03-08       Impact factor: 1.355

3.  Lysosomal escaped protein nanocarriers for nuclear-targeted siRNA delivery.

Authors:  Xiuping Cao; Xinxin Shang; Yingshu Guo; Xiaofei Zheng; Wenxin Li; Di Wu; Li Sun; Shanliang Mu; Chuanen Guo
Journal:  Anal Bioanal Chem       Date:  2021-03-26       Impact factor: 4.142

Review 4.  Accum™ Technology: A Novel Conjugable Primer for Onco-Immunotherapy.

Authors:  Abed El-Hakim El-Kadiry; Simon Beaudoin; Sebastien Plouffe; Moutih Rafei
Journal:  Molecules       Date:  2022-06-13       Impact factor: 4.927

5.  Antibody-Drug Conjugate that Exhibits Synergistic Cytotoxicity with an Endosome-Disruptive Peptide.

Authors:  Kelsey E Knewtson; Chamani Perera; David Hymel; Zhe Gao; Molly M Lee; Blake R Peterson
Journal:  ACS Omega       Date:  2019-07-31

6.  Promoting antigen escape from dendritic cell endosomes potentiates anti-tumoral immunity.

Authors:  Jean-Pierre Bikorimana; Natasha Salame; Simon Beaudoin; Mohammad Balood; Théo Crosson; Jamilah Abusarah; Sebastien Talbot; Raimar Löbenberg; Sebastien Plouffe; Moutih Rafei
Journal:  Cell Rep Med       Date:  2022-02-25

7.  Targeted Radionuclide Therapy Using Auger Electron Emitters: The Quest for the Right Vector and the Right Radionuclide.

Authors:  Malick Bio Idrissou; Alexandre Pichard; Bryan Tee; Tibor Kibedi; Sophie Poty; Jean-Pierre Pouget
Journal:  Pharmaceutics       Date:  2021-06-29       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.